Monday, November 19, 2018

Australian Kazia Therapeutics Presents ‘Trial in Progress’ Data for Glioblastoma Study

Results for GDC-0084, an investigational drug being being developed by Australian- based and oncology-focused Kazia Therapeutics and currently in human trials for the treatment of patients with glioblastoma, the most common and most aggressive form of primary brain cancer in adults, and several other forms of brain cancer were presented during the annual meeting of the Society for Neuro-Oncology...

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results

Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; DNAtrix) followed by standard dosing with pembrolizumab (Keytruda®; Merck Sharp & Dohme Corp/MSD) every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma, demonstrate that combination of the two agents is well tolerated...

Scientists, Physicians and Patients Collaborate to Improve Treatment of EGFR-Positive Lung Cancer

The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters have announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living with Epidermal Growth Factor Receptor (EGFR) positive lung cancer develop resistance to treatment over time, or do not respond at...

Isofol Initiates Pivotal Phase III Clinical Trial of Arfolitixorin for Metastatic Colorectal Cancer

Sweden-based Isofol Medical has initiated their pivotal Phase III clinical trial, called the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Arfolitixorin is a new drug candidate primarily developed to increase the efficacy of the cytotoxic agent 5‑fluorouracil (5-FU) in the treatment of patients with advanced colorectal cancer and as a rescue drug after high-dose methotrexate...

Pancreatic Cancer Risk in Adulthood Affected by Weight During Adolescence

Adolescent obesity may increase the risk of pancreatic cancer later in life with up to a four-fold increased risk. This is the conclusion of a study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results also suggest that overweight and even higher weight within the normal weight range in men may increase pancreatic...

New Immunotherapeutic Agent for the Treatment of 5T4-positive Solid Tumors Shows Promise

Preclinical data for ALG.APV-527, a new immunotherapeutic candidate for the treatment of a variety of 5T4-positive solid tumors, being presented at the 33rd annual meeting of the Society for Immunotherapy of Cancer's (SITC) held in Washington, D.C., November 9-11, 2018, confirms that the investigational agent selectively activates and enhances tumor-directed T-cell and Natural Killer (NK) cell responses. The investigational agent...

Phase II Trial Evaluating Lurbinectedin Shows Notable Efficacy in BRCA 1 and 2

Patients with BRCA1 or BRCA2-mutated metastatic breast cancer may benefit from treatment with lurbinectedin (PM1183 | Zepsyre®; PharmaMar), a selective inhibitor of active transcription of protein-coding genes. This is the outcome from a Phase II study. The results of this study were published in The Lancet Oncology and the Journal of Clinical Oncology and present noteworthy clinical activity in patients...

Investigational Compound from Chinese Tree Bark Shows Potential as Treatment for Pancreatic Cancer

A new compound found in the bark of a rare Chinese tree, called FL118, has powerful anticancer properties and a low toxicity profile. This is what researchers at Roswell Park Comprehensive Cancer Center observed in a study funded by grants from the National Cancer Institute and by donations to Roswell Park The results of their study outlining the effect...

New Partnership Attacks Disparities in Cancer Outcomes

The National Cancer Institute (NCI) has awarded $2.17 million grant to develop a joint cancer drug discovery and development and research education program to focus on cancers that have increased risk of incidence and/or mortality among underserved communities, ethnic populations such as African-Americans, Latinos and Native Americans who bear a disproportionate burden of cancer compared with other groups The new...

Brentuximab Vedotin Included in New Supplemental BLA for Peripheral T-cell Lymphoma

Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA). The submission is based on data from the phase III ECHELON-2 trial evaluating brentuximab vedotin in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL). The positive topline results of the Phase...

Related articles